Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study
Open Access
Abstract
New bone formation is one of the hallmark characteristics of ankylosing spondylitis, which is thereby associated with syndesmophytes. Fetuin-A is a molecule that is abundantly found in calcified tissues and it shows high affinity for calcium phosphate minerals and related compounds. Considering the role of fetuin-A in the regulation of calcified matrix metabolism, we compared the fetuin-A levels in ankylosing spondylitis patients with syndesmophytes with those in patients without syndesmophytes and in healthy controls. We also studied other biomarkers that are thought to be related to syndesmophytes. Ninety-four patients (49 patients without syndesmophytes, 67.3% male, 40.7±8.7 years; 45 patients with syndesmophytes, 71.1% M, 43.9±9.9 years) and 68 healthy controls (44.2±10.6 years and 70.6% male) were included in this study. Syndesmophytes were assessed on the lateral radiographs of the cervical and lumbar spine. The serum levels of fetuin-A, dickkopf-1, sclerostin, IL-6, high-sensitivity C-reactive protein and bone morphogenetic protein-7 were measured with an enzyme-linked immunosorbent assay. Patients with syndesmophytes had significantly higher levels of fetuin-A compared with patients without syndesmophytes and controls (1.16±0.13, 1.05±0.09 and 1.08±0.13 mg/ml, respectively). However, fetuin-A was not different between the patients without syndesmophytes and controls. Bone morphogenetic protein-7 was significantly lower; dickkopf-1 was significantly higher in patients with ankylosing spondylitis compared with controls. The sclerostin concentrations were not different between the groups. In regression analysis, fetuin-A was an independent, significant predictor of syndesmophytes. Our results suggest that fetuin-A may a role in the pathogenesis of bony proliferation in ankylosing spondylitis.Keywords
This publication has 36 references indexed in Scilit:
- Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?Arthritis Research & Therapy, 2012
- Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytesAnnals of the Rheumatic Diseases, 2007
- Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitisJoint Bone Spine, 2007
- Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitisJournal of Clinical Investigation, 2005
- The immunohistochemical localization of 2-Heremans-Schmid glycoprotein/fetuin-A (AHSG)Nephrology Dialysis Transplantation, 2005
- A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.1994
- A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.1994
- Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.1994
- Fetuin ‐ an old friend revisitedBioEssays, 1992
- CHANGES IN THE SERUM ALPHA GLYCOPROTEIN DISTRIBUTION IN TRAUMA PATIENTS1975